Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-25-011735
Filing Date
2025-03-10
Accepted
2025-03-10 17:00:36
Documents
19
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A cpix-20250310.htm   iXBRL DEF 14A 561824
5 cpix-20250310_g1.jpg GRAPHIC 37721
6 cpix-20250310_g2.jpg GRAPHIC 10605
7 cpix-20250310_g3.jpg GRAPHIC 101206
8 cpix-20250310_g4.jpg GRAPHIC 12534
9 cpix-20250310_g5.jpg GRAPHIC 2405
  Complete submission text file 0001628280-25-011735.txt   1419733

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250310.xsd EX-101.SCH 3629
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250310_lab.xml EX-101.LAB 6935
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250310_pre.xml EX-101.PRE 4973
21 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250310_htm.xml XML 42819
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 25724638
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)